By indication / Hepatobiliary and pancreatic cancer
Hepatobiliary and pancreatic cancer
8 imaging agents and 14 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [18F]fluoro-2-deoxy-D-galactose | F-18 | — | 2 |
| [18F]fluoroacetate | F-18 | — | 2 |
| [68Ga]Ga-FAP-2286 paired with [177Lu]Lu-FAP-2286 | Ga-68 | — | 2 |
| [11C]SSI-4 | C-11 | Preclinical | 1 |
| [18F]AlF-NOTA-FAPI-04 | F-18 | — | 1 |
| [18F]AlF-NOTA-RD2 | F-18 | Preclinical | 1 |
| [68Ga]Ga-FAPI-74 | Ga-68 | — | 1 |
| [18F]L-Glutamic | F-18 | Clinical research |
Therapy
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [188Re]Re-188-HDD/lipiodol | Re-188 | Clinical research | 3 |
| [90Y]Y-L4-Lipo/ | Y-90 | Preclinical | 3 |
| [177Lu]Lu-Gemini | Lu-177 | — | 2 |
| [90Y]Y-90-ITGA6B4 | Y-90 | — | 2 |
| [177Lu]Lu-FAP-2286 paired with [68Ga]Ga-FAP-2286 | Lu-177 | Clinical research | 1 |
| [131I]I-131-SFMS | I-131 | — | 1 |
| [177Lu]Lu-DTPA-PODSAJICAP-5B1 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-FD1 paired with [68Ga]DOTA-FD1 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-FD2 paired with [68Ga]DOTA-FD2 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-2P(FAPI)2 | Lu-177 | Preclinical | |
| [166Ho]Ho-166-PLLA | Ho-166 | — | |
| [90Y]Y-microsphere | Y-90 | Approved | |
| [211At]At-211-AMT paired with [11C]AMT | At-211 | Preclinical | |
| [212Pb]Pb-DO3A-PEG7-Tz | Pb-212 | Preclinical |
Other entries
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [68Ga]Ga-DATA5m.SA.FAPi | Ga-68 | Clinical research | 1 |
| [64Cu]CuCl2 | Cu-64 | Clinical research | 1 |
| [177Lu]Lu-lipiodol | Lu-177 | Preclinical | |
| [166Ho]Ho-labeled microspheres | Ho-166 | Preclinical |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region - tell us what you need.
Get in touch